Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

Authors

Sandra M. Swain, Medstar Washington Hospital Center, Washington, DC
Michael S. Ewer, University of Texas M.D. Anderson Cancer Center
Javier Cortes, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Dino Amadori, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
David Miles, Mount Vernon Cancer Centre, Middlesex, United Kingdom
Adam Knott, Roche Products, Welwyn, United Kingdom
Emma Clark, Roche Products, Welwyn, United KingdomFollow
Mark C. Benyunes, Genentech, South San Francisco, CA
Graham Ross, Roche Products, Welwyn, United Kingdom
Jose Baselga, Memorial Sloan-Kettering Cancer Center, Memorial Hospital

Document Type

Journal Article

Publication Date

3-2013

Journal

Oncologist

Volume

Volume 18, Issue 3

Inclusive Pages

257-264

Keywords

Antibodies; Monoclonal; Humanized--adverse effects; Antibodies; Monoclonal; Humanized--therapeutic use; Antineoplastic Combined Chemotherapy Protocols--adverse effects; Antineoplastic Combined Chemotherapy Protocols--therapeutic use; Breast Neoplasms--drug therapy; Receptor; erbB-2--biosynthesis; Ventricular Dysfunction; Left--chemically induced

Comments

This is a PubMed Central article. Click on link for full-text access.

APA Citation

Swain, S. M., Ewer, M. S., Cortés, J., Amadori, D., Miles, D., Knott, A., . . . Baselga, J. (2013). Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study. Oncologist, 18(3), 257-264.

Peer Reviewed

1

Open Access

1